Aripiprazole Tablet
Product Images NDC 50090-7105

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 50090-7105). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure2 (2f5cad93 Figure 02)

A chart titled 'Effect of Other Drugs on Aripiprazole' showing the fold change and 90% confidence intervals for dehydro-aripiprazole levels relative to a reference without interacting drugs. It compares pharmacokinetic parameters AUC and Cmax across various interacting drugs including ketoconazole, quinidine, carbamazepine, famotidine, valproate, and lorazepam.*

FDA Label Image

Figure3 (2f5cad93 Figure 03)

A horizontal bar chart illustrating the effect of aripiprazole on the pharmacokinetic parameters of various drugs metabolized by enzymes such as CYP2D6, CYP2C9, 2C19, UGT1A4, and others. The chart presents fold change and 90% confidence intervals for parameters including AUC, Cmax, DM/DRP ratio, and INR relative to a reference without interacting drug.*

FDA Label Image

Figure4 (2f5cad93 Figure 04)

A pharmacokinetic chart showing aripiprazole fold change and 90% confidence intervals in special populations. It compares AUC and Cmax changes relative to reference for factors including CYP2D6 metabolizer status, gender, age groups, hepatic impairment, and severe renal impairment, with data points and error bars illustrating variability.*

FDA Label Image

Figure 5 (2f5cad93 Figure 05)

A pharmacokinetic chart titled 'Dehydro-Aripiprazole Fold Change and 90% CI' showing changes in AUC and Cmax relative to reference values. It compares factors like CYP2D6 metabolizer status, gender, age groups, hepatic impairment levels, and severe renal impairment with plotted points and error bars illustrating fold changes and confidence intervals.*

FDA Label Image

6 (2f5cad93 Figure 06)

A Kaplan-Meier plot displaying the proportion of relapse over days from randomization for two groups: Aripiprazole and Placebo. The y-axis represents the proportion with relapse, and the x-axis shows days from randomization up to 182. A table below the graph indicates the number of subjects at risk at various time points for both groups.*

FDA Label Image

7 (2f5cad93 Figure 07)

A line graph displaying the proportion of subjects with relapse over time (days from randomization) comparing aripiprazole versus placebo. The x-axis shows days from 0 to 182, and the y-axis represents the proportion with relapse from 0 to 1. The graph includes the number of subjects at risk at various time points for both aripiprazole and placebo groups.*

FDA Label Image

8 (2f5cad93 Figure 08)

A line graph comparing the proportion of subjects with relapse over time between Aripiprazole and placebo groups. The x-axis represents days from randomization up to 364 days, and the y-axis shows the proportion with relapse ranging from 0 to 1. The chart includes the number of subjects at risk for each group at different intervals.*

FDA Label Image

Figure1 (Figure1.png)

A pharmacokinetic chart titled 'Effect of Other Drugs on Aripiprazole' showing fold changes and 90% confidence intervals for aripiprazole AUC and Cmax. The x-axis represents change relative to reference (without interacting drug) from 0 to 3. The chart lists interacting drugs by category, including CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, other valproate, and lorazepam, with corresponding fold changes shown as black squares with error bars.*

FDA Label Image

Figure9 (Image 01)

A line graph showing the change in YGTSS total tic score from baseline over 8 weeks of treatment comparing Aripiprazole at low and high doses versus placebo. The y-axis represents least-squares mean change in YGTSS total tic score, and the x-axis represents weeks of treatment. Three lines depict reductions in tic scores, with Aripiprazole high dose showing the greatest decrease over time, followed by low dose, and placebo showing the least change.*

FDA Label Image

Label Image (Lbl500907105)

ARIPIPRAZOLE 2 mg oral tablets packaging label from A-S Medication Solutions. The label states that each tablet contains 2 mg of aripiprazole and includes storage instructions to keep between 68 to 77 degrees Fahrenheit. The package contains 30 tablets.*

FDA Label Image

C:\users\ra\desktop\aripiprazole-plr\structure.jpg (Structure)

Chemical structure diagram of aripiprazole, the active ingredient of ARIPIPRAZOLE tablets. The diagram shows the molecular arrangement including chlorine atoms, aromatic rings, and nitrogen-containing groups consistent with aripiprazole's chemical composition.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.